摘要
目的探讨哌拉西林他唑巴坦不同途径治疗下呼吸道感染的疗效。方法选取武汉科技大学附属天佑医院2021年3月—2022年2月收治的下呼吸道感染患者112例,按随机数字表法分为观察组和对照组,各56例。对照组静脉滴注哌拉西林他唑巴坦治疗,观察组微泵哌拉西林他唑巴坦治疗,对比2组的疗效。结果观察组总有效率为91.07%,对照组为75.00%,观察组高于对照组,差异有统计学意义(P<0.05);治疗后,观察组的白细胞计数(white blood cell,WBC)、C反应蛋白(C-reactive protein,CRP)、降钙素原(procalcitonin,PCT)及白细胞介素-6(interleukin-6,IL-6)分别为(6.23±0.98)×10^(9)/L、(16.54±0.98)mg/L、(0.34±0.11)ng/mL、(16.57±5.87)pg/mL,对照组分别为(8.41±1.02)×10^(9)/L、(30.45±0.66)mg/L、(0.56±0.17)ng/mL、(27.69±6.02)pg/mL,观察组低于对照组,差异有统计学意义(P<0.05)。对照组不良反应发生率为10.71%,观察组为8.93%,观察组低于对照组,差异有统计学意义(P<0.05)。结论哌拉西林他唑巴坦微泵治疗下呼吸道感染可更好地改善症状及炎症指标,安全有效。
Objective To investigate the therapeutic efficacy of piperacillin-tazobactam administered via different routes for the treatment of lower respiratory tract infections.Methods A total of 112 patients with lower respiratory tract infection admitted to Tianyou Hospital Affiliated to Wuhan University of Science and Technology from March 2021 to February 2022 were selected and divided into an observation group and a control group according to the random number table method,with 56 cases in each group.The control group was treated with intravenous drip of piperacillin-tazobactam,while the observation group was treated with piperacillin-tazobactam via microinfusion pump.The therapeutic effects of the two groups were compared.Results The total effective rate was 91.07%in the observation group and 75.00%in the control group,with the observation group showing a higher rate than the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of white blood cell count(WBC),C-reactive protein(CRP),procalcitonin,(PCT),and interleukin-6(IL-6)in the observation group were(6.23±0.98)×10^(9)/L,(16.54±0.98)mg/L,(0.34±0.11)ng/mL,and(16.57±5.87)pg/mL respectively,while those in the control group were(8.41±1.02)×10^(9)/L,(30.45±0.66)mg/L,(0.56±0.17)ng/mL,and(27.69±6.02)pg/mL respectively.The observation group had lower levels than the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions was 10.71%in the control group and 8.93%in the observation group,with the observation group having a lower incidence than the control group,and the difference was statistically significant(P<0.05).Conclusion Micropump infusion of piperacillin-tazobactam for the treatment of lower respiratory tract infections demonstrated superior improvement in symptoms and inflammatory markers,indicating a safe and effective therapeutic approach.
作者
张亚迎
李雪梅
ZHANG Yaying;LI Xuemei(Department of Pharmacy,Tianyou Hospital Affiliated to Wuhan University of Science and Technology,Wuhan Hubei 430064,China)
出处
《中国卫生标准管理》
2025年第14期137-140,共4页
China Health Standard Management
关键词
哌拉西林他唑巴坦
泵注
静脉滴注
下呼吸道感染
疗效
炎症指标
piperacillin tazobactam
pumping
intravenous infusion
lower respiratory tract infection
efficacy
inflammatory index
